Peanut (Ara h 3) IgE

If you have ever wondered whether a reaction to peanut was a true allergy or something less serious, this test looks at one specific piece of the puzzle. It measures whether your immune system has made antibodies against Ara h 3, one of the main storage proteins inside a peanut.

Knowing your level helps refine the picture beyond a standard whole-peanut allergy test. It is most informative when read alongside other peanut component results, especially Ara h 2, and it can shape decisions about avoidance, oral food challenges, and how to track allergy over time.

What This Antibody Actually Reflects

Ara h 3 (the third major peanut protein scientists identified) is a legumin, a type of seed storage protein in the 11S globulin family that peanuts use to fuel growth of a new plant. Your immune system can mistakenly label this protein as a threat and produce IgE (immunoglobulin E, the antibody class involved in allergic reactions) against it.

The blood test measures how much Ara h 3 specific IgE is circulating in your serum. A detectable level means your immune system has been sensitized to that protein. Sensitization is not the same as a clinical allergy, but it is a prerequisite for an IgE driven reaction when you eat peanut.

Peanut Allergy Diagnosis

Ara h 3 IgE adds specificity to peanut allergy testing but on its own catches relatively few true cases. In a meta analysis of peanut component testing, Ara h 3 IgE at a 0.35 kU/L cutoff had a sensitivity of about 39% and specificity of 88% for true peanut allergy, compared with Ara h 2 at roughly 83% sensitivity and 84% specificity.

In one UK based study, Ara h 3 had modest overall diagnostic accuracy (an AUC of about 0.67 on a scale where 1.0 is perfect) compared with Ara h 2, which scored above 0.9. In high risk US infants screened before their first peanut exposure, adding Ara h 1 or Ara h 3 to Ara h 2 did not improve the ability to predict who would react.

There is one setting where Ara h 3 earns more weight. In a Japanese pediatric study, requiring all three storage proteins (Ara h 1, Ara h 2, and Ara h 3) to be positive together pushed specificity above 90%, meaning very few false positives among children sent for oral food challenge. The trade off is that fewer true cases get caught when you demand all three.

One emerging caveat: recent work suggests that some of the apparent IgE binding to Ara h 1 and Ara h 3 in older studies may have reflected trace contamination of those preparations with Ara h 2 or Ara h 6, rather than independent reactivity. This is an active area of research that may temper some historical claims about Ara h 3 as a stand alone marker.

Severity and Reaction Risk

Sensitization to multiple peanut storage proteins is generally a worse pattern than sensitization to a single one. Co sensitization to Ara h 1 and/or Ara h 3 alongside Ara h 2 has been linked to more severe reactions in some studies, although Ara h 2 (and Ara h 6) carry most of the severity signal.

That said, the 2020 AAAAI Practice Parameter on peanut allergy states that the degree of sensitization, whether measured by skin testing or component IgE, does not reliably predict the severity of a reaction. Component results refine probability and pattern recognition, but they cannot promise you how a future reaction will unfold.

In a study of 100 children, the diversity and specific activity of peanut IgE, including IgE to Ara h 3, correlated with stronger basophil and mast cell activation (the cells that release histamine during an allergic reaction) and with clinical peanut allergy rather than tolerance. Put plainly, a broader IgE attack against more peanut proteins tends to mean a body more primed to react, even if the exact reaction severity remains hard to forecast.

Natural History and Resolution

Peanut allergy can resolve, especially in childhood. About 34% of infant peanut allergy resolved by age 10 in one Australian cohort of 156 children, and falling peanut specific IgE alongside rising IgG4 (a non reactive antibody class) is the pattern that tracks with this resolution. IgE to storage proteins like Ara h 3 tends to contract as part of that shift.

Persistent broad sensitization to Ara h 1, 2, and 3 at diagnosis is associated with longer lasting allergy, although Ara h 2 alone usually carries the prognostic signal.

Monitoring Oral Immunotherapy

For people undergoing peanut oral immunotherapy, a treatment that gradually exposes the immune system to peanut to build tolerance, Ara h 3 IgE generally falls over time while IgG4 rises. In a phase 2 study analyzing sera from 22 oral immunotherapy patients and 6 controls, treatment reduced IgE to peanut, Ara h 1, Ara h 2, and Ara h 3, and shifted the antibody profile toward a more tolerant pattern. The PALISADE trial similarly showed significant changes in Ara h 3 IgE during treatment in a large group of participants.

Why a Single Reading Can Fool You

Ara h 3 IgE is part of a panel, not a stand alone verdict. Most published studies center on Ara h 2 as the main marker, so the supporting evidence for Ara h 3 interpretation is thinner and the same number can mean different things depending on what other peanut components show. A confidently low or undetectable Ara h 3 does not rule out peanut allergy if Ara h 2 or Ara h 6 are elevated.

• Recent immunotherapy or biologic treatment: medications used in allergic disease can lower peanut specific IgE over months. Dupilumab produced about a 49% median reduction in peanut specific IgE in a study of children, and a single dose of etokimab significantly reduced peanut specific IgE by day 15 in adults. These are intentional treatment effects, not artifacts, but they will shift any future reading.
• Component testing alone cannot replace history: a positive Ara h 3 in someone who tolerates peanut without symptoms still means sensitization, not allergy. Skin testing, clinical history, and sometimes an oral food challenge remain part of the workup.
• Lab assay differences: different laboratories may use different platforms (ImmunoCAP, ALEX2, or others), and absolute values can vary. For trending, use the same lab when possible.

Tracking Your Trend

Peanut specific IgE levels are not static. They shift with age, with allergen exposure, and with treatment. A single number tells you only where you stand right now. What matters more is the direction of travel.

Get a baseline alongside Ara h 2, Ara h 6, and whole peanut IgE. If you are pursuing oral immunotherapy, retest at 3 to 6 months and then annually to confirm the expected drop in IgE and rise in IgG4. If you are watching for natural resolution in a child, annual testing is reasonable to track whether values are falling. If you are simply monitoring known sensitization without symptoms, every 1 to 2 years is enough unless something changes.

What to Do With an Out of Pattern Result

A high Ara h 3 IgE alongside a high Ara h 2 (and often Ara h 1 or Ara h 6) points toward true peanut allergy with potential for systemic reactions, and warrants an allergy specialist consultation rather than self interpretation. The combination of elevated storage protein IgE and a history of any peanut reaction is a strong signal to maintain strict avoidance and carry epinephrine until evaluated.

An isolated elevation in Ara h 3 with low Ara h 2 is less common and harder to interpret. In that situation, a basophil activation test (a specialized blood test that measures how your immune cells actually respond to peanut protein) or, in expert hands, an oral food challenge can clarify whether the sensitization translates to real world risk.

A low or undetectable Ara h 3 IgE is reassuring only in context. If Ara h 2 and Ara h 6 are also low and you have no history of reaction, peanut allergy is unlikely. If you have ever had a reaction, low Ara h 3 alone does not rule it out, and the workup should not stop there.